SEC Comment Letter for Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Feb 18, 2021
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: Feb. 18, 2021 · CIK: 0001764013 · Accession: 0000000000-21-002030
AI Filing Summary & Sentiment
File numbers found in text: 001-38906
Letter
United States securities and exchange commission logo February 18, 2021 Pamela Yanchik Connealy Chief Financial Officer Immunovant, Inc. 320 West 37th Street New York, NY 10018 Re:Immunovant, Inc. Form 10-K for Fiscal Year Ended March 31, 2020 Filed June 29, 2020 File No. 001-38906 Dear Ms. Connealy: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
February 18, 2021
Pamela Yanchik Connealy
Chief Financial Officer
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Re:Immunovant, Inc.
Form 10-K for Fiscal Year Ended March 31, 2020
Filed June 29, 2020
File No. 001-38906
Dear Ms. Connealy:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences